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0022-2836 © 2011 Elsevier Ltd. Open accThe Tyr402His polymorphism of complement factor H (FH) with 20 short
complement regulator (SCR) domains is associated with age-related
macular degeneration (AMD). How FH contributes to disease pathology
is not clear. Both FH and high concentrations of zinc are found in drusen
deposits, the key feature of AMD. Heterozygous FH is inhibited by zinc,
which causes FH to aggregate. Here, zinc binding to homozygous FH was
studied. By analytical ultracentrifugation, large amounts of oligomers were
observed with both the native Tyr402 and the AMD-risk His402
homozygous allotypes of FH and both the recombinant SCR-6/8 allotypes
with Tyr/His402. X-ray scattering also showed that both FH and SCR-6/
8 allotypes strongly aggregated at N10 μM zinc. The SCR-1/5 and SCR-16/
20 fragments were less likely to bind zinc. These observations were
supported by bioinformatics predictions. Starting from known zinc binding
sites in crystal structures, we predicted 202 putative partial surface zinc
binding sites in FH, most of which were in SCR-6. Metal site prediction web
servers also suggested that SCR-6 and other domains bind zinc. Predicted
SCR-6/8 dimer structures showed that zinc binding sites could be formed at
the protein–protein interface that would lead to daisy-chained oligomers. It
was concluded that zinc binds weakly to FH at multiple surface locations,
most probably within the functionally important SCR-6/8 domains, and
this explains why zinc inhibits FH activity. Given the high pathophysio-
logical levels of bioavailable zinc present in subretinal deposits, we discuss
how zinc binding to FH may contribute to deposit formation and
inflammation associated with AMD.© 2011 Elsevier Ltd. Open access under CC BY license.ress: s.perkins@medsch.ucl.ac.uk.
lated macular degeneration; FH, factor H; RPE, retinal pigment epithelium; sRPEd,
t; SCR, short complement regulator; AUC, analytical ultracentrifugation; AREDS,
TA, ethylenediaminetetraacetic acid; PDB, Protein Data Bank; HSA, human serum
ess under CC BY license.
715Zinc Binding to Homozygous CFHIntroduction
The complement system of the innate immune
system is activated by the alternative pathway
through the low-level spontaneous hydrolysis of
C3 to form C3u (also known as C3H2O), which leads
to a positive-feedback amplification of C3 cleavage
to form activated C3b.1–3 While complement is
targeted against pathogenic bacteria, complement-
mediated host cell damage is prevented by the
complement regulator factor H (FH), which acts as a
cofactor for factor I to cleave C3b, competes with
factor B to inhibit the formation of the C3 convertase
C3bBb, and accelerates the decay of C3bBb.4 FH is
constructed from 20 short complement regulator
(SCR) domains, each about 61 residues in length.5
The SCR domains in heterozygous and homozygous
FHs form a partially folded-back structure in
solution.6–8 FH binds to glycosaminoglycans on
the host cell surface through its C-terminal region
and to SCR-7, and this is followed by the decay-
accelerating and cofactor activity of FH against C3b
through the N-terminal region.9–11 FH binds to C3b
at SCR-1/4 and SCR-19/20.12 FH also binds to other
ligands such as C-reactive protein, M-protein of
Streptococci bacterium, and FH-binding protein of
Neisseria meningitides.13–16 FH also self-associates to
form dimer, trimer, and higher oligomers.8,17–19 FH
oligomerisation is strongly promoted by zinc,
followed by copper.20,21 X-ray scattering and ana-
lytical ultracentrifugation (AUC) experiments
showed that pooled native heterozygous FH aggre-
gates strongly in the presence of ≥10 μM zinc or
copper, and this is matched by the decrease in fluid-
phase FH activity.21
FH is genetically associated with age-related
macular degeneration (AMD), the most common
cause of blindness in the elderly in the Western
population.22–26 FH is also involved with atypical
haemolytic uraemic syndrome, membranoprolifera-
tive glomerulonephritis type II, and Alzheimer's
disease.27–29 Even with the analysis of over 100
genetic alterations, the molecular role of FH in these
diseases is still unclear.28 This lack of knowledge is
attributed in part to the multivalent weak affinities
of FH for its ligands, which makes experimental
studies difficult.30,31 A hallmark of early AMD is the
appearance and growth of subretinal pigment
epithelial deposits (sRPEds) that develop within
Bruch's membrane, an extracellular matrix layer
interposed between the retinal pigment epithelium
(RPE) and the choroidal vasculature.32–34 sRPEds
contain oxidised lipids, carbohydrates, cellular
materials, and over 140 aggregated proteins includ-
ing FH and other complement components. FH is
secreted by RPE cells or is delivered by the
choroidal blood circulation.22,26,35,36 Complement-
activation-related inflammation has been linked
with the formation of sRPEds.22,26,37 A Tyr402Hispolymorphism in FH SCR-7 is associated with 50%
of AMD cases.23–26 The SCR-6/8 His402 allotype
shows slightly greater self-association than the
Tyr402 allotype.8,17 While the binding of C-reactive
protein to FHwas recently disputed, the most recent
study confirmed that the two proteins interact with
each other and that the SCR-6/8 His402 allotype
binds more weakly to C-reactive protein than the
Tyr402 allotype.4,13,30 The two FH allotypes showed
similar cofactor activity in C3b degradation.12,38 The
effect of glycosaminoglycans on these two FH
allotypes remains unclear, sometimes with
conflicting results.39
Zinc is abundant in the human retina.40 It is vital
for retinal cell survival and the functioning of
antioxidant enzymes and the visual cycle, while an
excess of zinc can be detrimental and exacerbate
neuronal damage.41 Under oxidative stress during
light exposure, the secretion of zinc from the zinc-
rich RPE cells is elevated.41 Millimolar concentra-
tions of zinc have been found in sRPEds and Bruch's
membrane in AMD, suggesting that the pathological
release of zinc from surrounding tissues like the
RPE–choroid complex might be involved in deposit
formation.40,42 Studies of the effect of zinc supple-
ments on reducing the development of AMD gave
different results. Based on the premise that zinc is an
antioxidant in retina, the large Age-Related Eye
Disease Study (AREDS) indicated that supplements
with zinc alone or with zinc together with vitamins
C and E and β carotene reduce the risk for
progression to advanced AMD.43,44 Interestingly, a
follow-up study found that the treatment response
to the AREDS-recommended zinc supplement was
influenced by the Tyr402His FH polymorphism. A
smaller reduction in the progression to AMD to
advanced stage disease was found in patients with
the FH His402 allotype than in those with the FH
Tyr402 allotype.45
Zinc binding sites show a tetrahedral coordina-
tion geometry at which the binding site is often
formed from surface His, Asp, Glu, and Cys
residues.46 When these zinc sites are found
between two protein surfaces, between one and
three residues at each surface contribute to a
tetrahedral coordination involving four residues.
The Tyr402His polymorphism potentially pro-
vides a new His zinc-binding ligand within
the SCR-6/8 region that binds to heparin and
C-reactive protein. To clarify whether the two
allotypes exhibit different zinc binding proper-
ties, we studied the homozygous FH Tyr402 and
His402 allotypes and the two allotypes of
recombinant SCR-6/8 titrated with zinc. By
AUC and synchrotron X-ray scattering, we
showed that zinc interacts with both homozygous
allotypes of FH. We also studied the effect of zinc
on the other functionally important SCR-1/5 (binds
C3b) and SCR-16/20 (binds C3b, C3d, C-reactive
Fig. 1. Sedimentation velocity analyses of the two FH allotypes titrated with zinc. Both allotypes were studied at
0.7 mg/ml. In the sedimentation boundary fits, only every 10th scan is shown for clarity. (a–d) The fits corresponding to
the FH Tyr402 allotype (026II; blue) was titrated with zinc concentrations of 20 μM, 60 μM, 120 μM, and 200 μM in that
order. (f–i) The fits corresponding to the FH His402 allotype (027BA; red) was titrated with the same zinc concentrations.
(e and j) The averaged c(s) sedimentation coefficient distribution analyses from each of (a) to (c) and (f) to (h) are shown for
the FH Tyr402 and FH His402 allotypes, respectively. The height of the FH monomer peak close to 5.7 S is normalised to
100 for clarity. The zinc concentrations (μM) are denoted numerically.
716 Zinc Binding to Homozygous CFHprotein, and heparin) regions. Bioinformatics pre-
dictions supported the observation of zinc binding
to SCR-6/8 and less so to SCR-1/5 or SCR-16/20.We discuss the molecular implications of our
results with FH and zinc for complement regulation
and sRPEd formation in AMD.
Fig. 2. Dependence of the monomer and oligomers of
FH and SCR-6/8 on zinc concentrations. (a) The values
from c(s) integrations correspond to the averages obtained
at 50,000 rpm and 60,000 rpm. The oligomer data were
fitted to a two-parameter power function, y=a×(1+x)b,
and the monomer data were fitted to the function f=y0
+a×xb. Oligomers are denoted by filled symbols, and
monomers are denoted by open symbols for four
experiments with two FH Tyr402 (026II, 022LM, blue, ●,
○,▲,Δ) and two FHHis402 (027BA, 032KO, red,●,○,▲,
Δ) allotypes. (b) The proportions of monomer of the
Tyr402 (blue) and His402 (red) allotypes of SCR-6/8 are
shown.
717Zinc Binding to Homozygous CFHResults and Discussion
Sedimentation velocity of the complexes of the
two FH and SCR-6/8 allotypes with zinc
The homozygous full-length FH and recombinant
SCR-6/8 allotypes (Tyr402 and His402) were purified
(Materials and Methods). During this study, the two
FH allotypes were studied at a concentration of
0.7–0.8mg/ml (4.6–5.2 μM) in order to be comparable
in concentration with the physiological FH range of
0.235–0.810 mg/ml in serum.28 The SCR-6/8 allo-
types were studied at 0.3 mg/ml (14.6 μM), which
was the lowest concentration that produced analy-
sable data. Both proteins were studied in Hepes
buffer (Materials and Methods) in order to avoid the
precipitation of zinc with phosphate. Both were
titrated with 0–600 μM ZnSO4 in ultracentrifugation
and scattering experiments.
AUC studies the sedimentation behaviour of
macromolecules on subjecting these to a high
centrifugal force in order to determine their sizes
and shapes.47 Sedimentation velocity experiments
were performed using speeds of up to 60,000 rpm on
two freshly prepared Tyr402 and two His402 FH
allotypes at concentrations of 0.7–0.8 mg/ml, each
being titrated with zinc from 0.2 μM to 200 μM.
Similar sets of rapidlymoving sedimentation bound-
aries were observed for both allotypes when [Zn]
increased. Good fits to the sedimentation boundaries
were obtained in all cases using sedimentation
coefficient distribution analyses c(s) (Fig. 1a–d and
f–i). At all [Zn] values, the FH monomer was
observed at a mean value of 5.67±0.05 S for the
Tyr402 allotype and at 5.74±0.07 S for the His402
allotype at 50,000 rpm. This indicated the presence of
zinc-free FH even with a 40-fold excess of zinc,
meaning that the binding of zinc is weak. For both
allotypes with [Zn] between 0.2 and 20 μM, addi-
tional peaks that corresponded to similar small
amounts of oligomers from dimers to nonamers
were visible from 7 S to 30 S that resembled those for
zinc-free FH.7,8,19 For both allotypes with [Zn]
between 60 and 200 μM, sizeable amounts of rapidly
sedimenting species were observed with increased
s20,w values of up to 100 S in the c(s) distributions
(Fig. 1e and j). The proportions of oligomers of the
FH Tyr402 and His402 allotypes were derived by
integration of the c(s) size distribution analyses. No
differences in the proportions of the FH monomer
and oligomers at each zinc concentration were seen
between the allotypes. Like heterozygous pooled
native FH,21 both the Tyr402 and the His402
allotypes form heavy oligomers with zinc and
share similar dependences on [Zn] (Fig. 2a).
The sedimentation boundaries showed that dif-
ferential ranges of S values for the zinc-induced FH
oligomers were formed with the two allotypes. Forthe Tyr402 and His402 allotypes with zinc in high
excess at 200 μM, the oligomer peaks ranged in size
with variable amounts in repeated runs with S
values in excess of 100 S, indicating their sensitivity
to the presence of zinc when zinc was in excess.
These differences were reflected in Fig. 1a–d and f–i,
where the upper part of the boundaries sedimented
more rapidly for the Tyr402 and His402 allotypes at
all zinc concentrations. In addition, with the use of
the homozygous FH proteins whose genetic hetero-
geneity is much reduced compared to the pooled FH
used in earlier studies, it was noteworthy that the c
(s) peaks show no sequence of well-resolved peaks
with well-defined S values similar to the individual
peaks 2–9 seen in zinc-free full-length FH.7,8,19 These
further observations suggested that a broad range of
zinc-induced FH oligomers of different sizes was
718 Zinc Binding to Homozygous CFHformed through the cross-linking of different weak
zinc binding sites at the surface of FH.
In order to clarify the molecular basis for zinc-
induced FH oligomers, we performed sedimenta-
tion velocity experiments at 50,000 rpm on the
Tyr402 and His402 allotypes of the SCR-6/8 frag-
ment at 0.3 mg/ml (14.6 μM) titrated with zinc from
0.2 μM to 600 μM. Similar sedimentation boundaries
were observed for the two allotypes of SCR-6/8 at
each [Zn] (Fig. 3a–d). In contrast to full-length FH,
no rapidly sedimenting larger species were detectedFig. 3. Sedimentation velocity analyses of the two SCR-6/8
0.3 mg/ml. In the sedimentation boundary fits, only every 10th
8 Tyr402 allotype (blue) titrated with zinc at 6 μM and 200 μM
titrated with zinc at 6 μM and 200 μM. (e) The c(s) sedimentati
with 6 μM (blue) and 200 μM (cyan) zinc, and the His402 al
distributions are labelled with their zinc concentration values (
and that at about 4.0 S is the dimer.in the size distribution c(s) fits at any [Zn]. The c(s)
analyses consistently showed a major monomer
peak at 2.12±0.09 S and a minor dimer peak at
4.03±0.20 S for the Tyr402 allotype and, likewise,
two peaks at 2.19±0.08 S and 3.95±0.16 S for the
His402 allotype (Fig. 3e). This agrees with the
previous observation of SCR-6/8 monomer and
dimer by sedimentation velocity, where the assign-
ment of monomer and dimer was made based on the
molecular weights derived from the c(s) analyses.17
However, with [Zn] above 60 μM, the signalallotypes titrated with zinc. Both allotypes were studied at
scan is shown for clarity. (a and b) The fits for the SCR-6/
. (c and d) The fits for the SCR-6/8 His402 allotype (red)
on coefficient distribution analyses for the Tyr402 allotype
lotype with 6 μM (red) and 200 μM (pink) zinc. The c(s)
μM). The peak at about 2.1 S corresponds to the monomer,
719Zinc Binding to Homozygous CFHintensity of the monomer peak for both allotypes
decreased significantly with an increase in [Zn]
(Figs. 2b and 3e). This indicates that, at [Zn] above
60 μM, zinc induced the formation of aggregated
SCR-6/8, which were sufficiently large to sediment
to the bottom of the sample cell before the first
boundary scan was recorded. While the His402
allotype showed slightly greater aggregation than
the Tyr402 allotype, this may result from experi-
mental variability in quantifying the different
sedimenting species. Overall, it was noteworthy
that SCR-6/8 aggregated at the same [Zn] value that
caused large FH oligomers to form. This indicated
that the major binding sites for zinc in full-length FH
were located within SCR-6/8.
The reversibility of the zinc-induced aggregation
of the SCR-6/8 allotypes was studied by adding
2mM ethylenediaminetetraacetic acid (EDTA) to the
ultracentrifuge cell containing 0.3 mg/ml SCR-6/
8 and 300 μM zinc. After mixing, we immediately re-
ran the sedimentation velocity experiment at
50,000 rpm on this cell again. Even though the size
distribution c(s) analyses showed that the monomer
peak for both allotypes of SCR-6/8 with 300 μMzinc
was much reduced, the addition of EDTA caused a
significant increase in the monomer peak intensity
for both allotypes (Fig. 4). This showed that the zinc-
induced aggregation of SCR-6/8 was reversible, in
good agreement with the reversibility of the zinc-
induced oligomers of heterozygous pooled FH by
adding EDTA.21
Additional ultracentrifugation experiments with
the SCR-1/5 and SCR-16/20 fragments in the
presence of zinc were performed as controls of
the SCR-6/8 experiments. SCR-1/5 is less soluble
at 0.3 mg/ml when expressed, compared to
SCR-6/8 and SCR-16/20. As [Zn] increased,
SCR-1/5 aggregated in the same manner asSCR-6/8 at a similar [Zn] value to that for SCR-6/8,
and this may reflect its lower solubility. This was
visible from both the reduced intensities of the
fringes as [Zn] increased and the marked reduc-
tion in the monomer peak intensity in the c(s) plot
(Fig. 5a–d). In contrast to this, SCR-16/20 is more
soluble than SCR-1/5 and SCR-6/8, and SCR-16/20
remained in solution as [Zn] increased with a smaller
reduction in the number of observed fringes at
600μM.Here, the c(s) plot showed a smaller reduction
in the sizes of themonomer and dimer peaks, while at
the same time, as many as three other species were
observed (peaks 1, 2, and 3 in Fig. 5e–h). These
experiments showed that other zinc-induced oligo-
mers formed in two other regions of FH. However,
unlike SCR-6/8, both SCR-1/5 and SCR-16/20
possessed His6-tags that may comprise potential
zinc binding sites.18 This possibility was evaluated
by further zinc titrations in which a 2:1 molar ratio of
nickel (17 μM) was present to saturate its binding site
at the His6-tag, to which nickel binds more tightly
with a dissociation constant of 1 μM than zinc.48
The resulting c(s) plots showed that no SCR-1/5 or
SCR-16/20 aggregates were seen and that only the
monomer or monomer/dimer peaks that were
similar to those observed for zinc-free protein were
observed. These final experiments indicate either that
the His6-tag represented an oligomeric zinc binding
site and this is eliminated by the stronger binding of
nickel to this or that nickel competes with zinc for
weak interaction sites in FH. The first explanation is
preferred because nickel has no strong effect on FH
oligomer formation.21 Three control experiments
with full-length FH His402 in the presence of
200 μM zinc and 20 μM nickel, 200 μM zinc, or
20 μM nickel were performed to complete these
studies. This showed that, in the presence of nickel,
zinc still causes full-length FH to aggregate in similarFig. 4. The effect of EDTA on the
interactions between the SCR-6/
8 allotypes and zinc using sedimen-
tation velocity. (a) The c(s) distribu-
tion analyses are shown for the
Tyr402 allotype in the presence of
0.2 μM zinc (blue continuous line),
300 μM zinc (cyan continuous line),
and 300 μM zinc and 2 mM EDTA
(cyan broken line). (b) The c(s)
distribution analyses are shown
for the His402 allotype in the
presence of 0.2 μM zinc (red con-
tinuous line), 300 μM zinc (pink
continuous line), and 300 μM zinc
and 2mMEDTA (pink broken line).
Fig. 5. Sedimentation velocity analysis of SCR-1/5 and SCR-16/20 titrated with zinc. Red numbers indicate zinc
concentrations (μM). (a–c) For SCR-1/5, the boundary fits at three zinc concentrations are shown for only every 24th scan out
of 480 scans for reason of clarity. (d) Size distribution c(s) analyses for SCR-1/5 at seven zinc concentrations are shown. M
indicates themonomer position. The graphswere displaced vertically in units of 0.5 for reason of clarity. (e–g) For SCR-16/20,
the boundary fits at three zinc concentrations are shown for only every 22nd scan out of 440 scans. (h) Size distribution c(s)
analyses for SCR-16/20 at seven zinc concentrations are shown.MandD indicate themonomer anddimerpeaks, respectively.
Weak emerging signals are denoted by 1, 2, and 3. Graphs are displaced vertically in units of 0.5 for reason of clarity.
720 Zinc Binding to Homozygous CFHquantities, even though zinc-induced oligomer for-
mation in SCR-1/5 and SCR-16/20 was individually
blocked by nickel. Even though these experiments are
cautionary in indicating that other weak zinc binding
sites in FH may exist, it was concluded that a major
region for zinc-binding to FH lies in SCR-6/8.X-ray scattering of the two allotypes of FH and
SCR-6/8 with zinc
X-ray scattering is a diffraction method used to
study the solution structures of macromolecules in
random orientations.49 The effect of zinc on the
721Zinc Binding to Homozygous CFHstructures of freshly purified two Tyr402 and two
His402 allotypes of full-length FH and the two
allotypes of FH fragment SCR-6/8 was investigated
by synchrotron X-ray scattering. FH was studied at
0.9 mg/ml (5.8 μM) in order to be comparable with
physiological FH concentrations, while SCR-6/8was
studied at 0.2 mg/ml (9.7 μM), this being the lowest
concentration of SCR-6/8 that produced analysableFig. 6. X-ray Guinier analyses of the full-length FH and SC
symbols correspond to the experimental data and the filled sym
line fits. Data correspond to one FH Tyr402 allotype (018DK) i
(d), and (f), both at 0.9 mg/ml, and SCR-6/8 Tyr402 (g and i) a
the Tyr402 allotype of FH and SCR-6/8 are shown in blue fro
600 μM ZnSO4. Data for the His402 allotype of FH and SCR-6
pink from 200 μM to 600 μMZnSO4. (a and b) Guinier RG plots
titrated with ZnSO4 concentrations of 0.2 μM (O), 2 μM (□), 6 μ
600 μM (Δ). The Q fit ranges were 0.08–0.13 nm−1 for 0.2 μM to
ZnSO4. The zinc concentrations are numerically labelled as sh
RXS-1 fits of ln I(Q)Q versus Q
2 for the two FH allotypes wit
corresponding Guinier cross-sectional RXS-2 fits for the two FH
h) Guinier RG plots for the SCR-6/8 Tyr402 and His402 alloty
0 μM (○), 2 μM (□), 6 μM (Δ), 20 μM (▿), 60 μM (◊), 120 μM (⎔
were 0.16–0.5 nm−1 for 0.2 μM to 120 μM ZnSO4 and 0.06
corresponding Guinier cross-sectional RXS fits for the SCR-6/data. Each FH or SCR-6/8 sample was titrated with
0 μM to 600 μM ZnSO4. The scattering data I(Q)
showed excellent signal-to-noise ratios and no
detectable effect from radiation damage.
Guinier fits at lowQ values (whereQ=4π sin θ/λ;
2θ, scattering angle; λ, wavelength) give the radius
of gyration (RG), which monitors the degree of
elongation of the protein, and the I(0)/c value,R-6/8 allotypes titrated with zinc. In all panels, the open
bols correspond to those used for the RG and RXS straight
n (a), (c), and (e) and one FH His402 allotype (030TJ) in (b),
nd SCR-6/8 His402 (h and j), both at 0.2 mg/ml. Data for
m 0.2 μM to 120 μM ZnSO4 and in cyan from 200 μM to
/8 are shown in red from 0.2 μM to 120 μM ZnSO4 and in
of ln I(Q) versus Q2 for FH Tyr402 and FHHis402 allotypes
M (Δ), 20 μM (▿), 60 μM (◊), 120 μM (⎔), 200 μM (O), and
120 μM ZnSO4 and 0.03–0.16 nm
−1 for 200 μM to 600 μM
own. (c and d) The corresponding Guinier cross-sectional
h zinc using a Q range of 0.16–0.26 nm−1. (e and f) The
allotypes with zinc using aQ range of 0.4–0.8 nm−1. (g and
pes at 0.2 mg/ml titrated with ZnSO4 at concentrations of
), 200 μM (O), 300 μM (□), and 600 μM (Δ). TheQ fit ranges
–0.11 nm−1 for 200 μM to 600 μM ZnSO4. (i and j) The
8 allotypes using a Q range of 0.55–1.0 nm−1.
722 Zinc Binding to Homozygous CFHwhich is proportional to the relative molecular mass
(Fig. 6a and b).49,50 At larger Q values, Guinier fits
give the cross-sectional radius of gyrationRXS, which
monitors the structural proximity relationships
between non-neighbouring SCR domains (RXS-1)
and neighbouring SCR domains (RXS-2) (Fig. 6c–f).
6
The overall folded-back SCR domain structure of
FH leads to the RXS-1 value, while the localized,
extended structural arrangement of SCR domainsFig. 7. Dependence of the RG, I(0)/c, and RXS values of FH
Tyr402 allotype is shown in blue, and the His402 allotype is sho
averaged, and statistical error bars are shown where visible. In
Tyr402 allotypes (018DK and 016CC) and FHHis402 allotypes
to 600 μM (each pair shown as broken and continuous lines).
8 allotypes titrated with the same zinc concentration range froleads to the RXS-2 value. In our previous study of
heterozygous and homozygous FHs, the presence
of oligomers caused concentration-dependent
increases in the values of RG and RXS-1.
8,19 Here,
at the lowest zinc concentration of 0.2 μM, the mean
RG and RXS-1 values were 8.91±0.17 nm and 3.03±
0.17 nm, respectively, for the Tyr402 FH allotype
and 9.23±0.72 nm and 3.15±0.39 nm, respectively,
for the His402 FH allotype (Fig. 7b and c). Both theand SCR-6/8 on the zinc concentration. In all cases, the
wn in red. Each value was measured in quadruplicate and
(a) to (d), the four titrations correspond to two pairs of FH
(030TJ and 033NV) at 0.9 mg/ml titrated with zinc from 0.2
In (e) to (g), the titrations correspond to the two SCR-6/
m 0.2 to 600 μM.
Fig. 8. Dependence of the distance distribution function
P(r) of the FH allotypes on zinc concentration. The P(r)
curves were calculated from the scattering curves of the
two FH Tyr402 allotypes (018DK and 016CC; blue) and
two FH His402 allotypes (030TJ and 033NV; red). From
bottom to top, the zinc concentrations were 6 μM, 20 μM,
60 μM, and 120 μM (labelled). The average value of the
most frequently occurring distance M for each allotype at
each zinc concentration is marked by vertical straight
lines.
723Zinc Binding to Homozygous CFHRG and the RXS-1 values were similar to those for
heterozygous FH at 0.9 mg/ml without zinc19 and
were the same within error of the corresponding
values for zinc-free homozygous FH at 1.1 mg/ml.8
When both the Tyr402 and the His402 FH allotypes
were titrated with zinc of up to 6 μM, the scattering
curves I(Q) remained unchanged (Fig. 6a–d), and the
Guinier values remained unchanged (Fig. 7a–c). For
[Zn] from 20 μM to 600 μM, the I(Q) intensities
increased significantly at low Q and decreased at
high Q as the result of oligomer formation (Fig. 6a–f).
The Guinier I(0)/c and RG values increased signifi-
cantly (Fig. 7a and b), although the RXS-1 and RXS-2
values decreased at [Zn] above 200 μM as the result
of the decrease in the intensity of I(Q) in the Q
ranges used for the RXS determinations (Figs. 6c–f
and 7c and d). The changes for both homozygous
FH allotypes are comparable with previous observa-
tions for heterozygous native FH,19 indicating again
that FH heterogeneity is not responsible for these
observations. For [Zn] between 20 μM and 120 μM,
the two His402 allotypes showed slightly higher
Guinier I(0)/c, RG, and RXS-1 values than the two
Tyr402 allotype (Fig. 7a–c). If this is significant,
this would indicate that the His402 allotype
formed more oligomers than the Tyr402 allotype;
however, the difference is not considered to be
large enough.
To test whether the Tyr402 and His402 allotypes
of SCR-6/8 formed zinc-induced oligomers, we
titrated both of them with [Zn] from 0.2 to 600 μM.
For SCR-6/8 at 0.2 mg/ml with 0.2 μM zinc, the
Guinier RG and RXS values were 2.63±0.46 nm and
0.88±0.29 nm, respectively, for the Tyr402 allotype,
which were similar to values of 2.79±0.47 nm and
1.00±0.27 nm for the His402 allotype. Those Guinier
values are slightly less but within error of the
experimental RG and RXS values of 3.26–3.35 nm and
1.04 nm, respectively, for the zinc-free Tyr402
allotype and 3.12–3.21 nm and 1.15 nm (±0.06–
0.20 nm) for the zinc-free His402 allotype.17 For [Zn]
between 0.2 μM and 6 μM, the scattering curves I(Q)
were unchanged for both allotypes (Figs. 6g–j and
7e–g). At 20 μM [Zn], the I(Q) curves of both
allotypes underwent dramatic changes in which the
intensities sharply increased at low Q and decreased
rapidly at large Q (Fig. 6g–j), and these changes
resulted in much increased Guinier I(0)/c and RG
values (Fig. 7e and f). Above 20 μM [Zn], the I(Q)
intensities continued to rise at very low Q (Fig. 6g
and h). The Guinier I(0)/c and RG values peaked at
[Zn] of 60 μM and declined at higher [Zn] values
(Fig. 7e and f). These changes showed that both
allotypes of SCR-6/8 interacted with zinc starting
from 10 μM, which is the same starting concentra-
tion as that of the FH interaction with zinc. Unlike
the FH–zinc oligomers, which remained in solution,
the changes observed for SCR-6/8 caused this to
aggregate, and this accounted for the apparentdecline in the I(0)/c and RG above 60 μM. Like full-
length homozygous FH, no significant difference
was observed for the zinc-induced oligomerisation
of the Tyr402 and His402 allotypes of SCR-6/8.
The distance distribution function P(r) of the two
FH allotypes provided shape information in real
space on the zinc-induced FH oligomers. The P(r)
curve summarises the distances between all pairs of
atoms within FH and gives the most frequently
occurring distance M from the position of the peak
maximum, the maximum length L from the point at
which P(r) becomes 0 at largeQ, and an independent
calculation of the RG and I(0) values for comparison
with the Guinier determinations (not shown).49 At
[Zn] of up to 6 μM, the shape of the P(r) curves
remained unchanged with an increase in [Zn] and
was indistinguishable between the Tyr402 and the
His402 FH allotypes (Fig. 8). The length L of both
allotypes was 32 nm, and the maximum M values
were at 5.36±0.11 nm and 5.20±0.11 nm for the
Tyr402 and His402 allotypes. These values are in
good agreement with previous observations for
heterozygous FH with zinc and showed that FH
has a folded-back domain structure with an overall
length L much reduced from a maximum length of
73 nm if its domains had been fully extended in their
arrangement.21 Also similar to previous observa-
tions, the intensity of the P(r) curves and the L andM
values for both allotypes increased with an increase
724 Zinc Binding to Homozygous CFHin [Zn] above 6 μM, which indicates that zinc-
induced oligomerisation occurred with both the
Tyr402 and the His402 allotypes and was not
dependent on heterogeneity (Fig. 8). The increase
in L values showed that the oligomers had increased
in size compared to the monomer. For [Zn] at 20 μM,
60 μM, and 120 μM, the shapes of the P(r) curves
were similar between the two allotypes, indicating
that oligomers that are similar in size and confor-
mation had formed under these conditions (Fig. 8).
The P(r) intensities and M values were slightly
higher for the His402 allotype than for the Tyr402
allotype, which is consistent with the Guinier
analyses; however, the difference is not considered
to be significant (Fig. 8). When the P(r) analyses
were repeated for the SCR-6/8 allotypes with [Zn]
of up to 6 μM, Lwas determined to be 9 nm for both
allotypes, and the curves were indistinguishable
between the two allotypes (data not shown). The P
(r) curves were similar in appearance to those for
SCR-6/8 without zinc.17 Above 6 μM zinc, the
aggregation of SCR-6/8 made further P(r) analyses
impossible. The lack of difference between the SCR-
6/8 allotypes indicated that His402 had no effect on
zinc-induced oligomerisation compared to Tyr402.
Fluid-phase activity assays of two allotypes of
full-length FH complexes with zinc
In order to test the impact of zinc on the regulatory
role of the Tyr402 and His402 FH allotypes, we
performed assays of fluid-phase ammonium-
inactivated C3 (C3u) cleavage by factor I and
two allotypes of FH by zinc titration.51 Previous
fluid-phase activity assays had been performed at
significantly lower FH concentrations that included
45 μg/ml,51 3 μg/ml,52 30 μg/ml,53 and 0.3 μg/ml54
than the 0.235–0.81 mg/ml (1.5–5.3 μM) observedFig. 9. Cleavage of fluid-phase C3u by FI and the two
FH allotypes in the presence of zinc. (a) Reducing SDS-
PAGE analysis of C3u cleavage by factor I and the FH
Tyr402 allotype (013HH) in the absence of zinc. Lane 1,
High Mark™ Prestained High Molecular Weight Stan-
dard; lane 2, 0.3 mg/ml C3u; lane 3, 0.3 mg/ml C3u and
0.3 mg/ml FH; lanes 4–15 correspond to lane 3 with
0.003 mg/ml factor I added with the reaction times in
minutes as labelled. FH and the α-chain and β-chain of
C3u are arrowed on the left, and the α-chain cleavage
products are arrowed on the right. (b) Reducing SDS-
PAGE analysis of C3u cleavage by factor I and the FH
Tyr402 allotype (013HH) with 200 μM zinc. Lane 1,
0.3 mg/ml C3u; lane 2, 0.3 mg/ml C3u and 0.3 mg/ml FH;
lane 3, 0.3 mg/ml C3u, 0.3 mg/ml FH, and 200 μM zinc;
lanes 4–15 correspond to lane 3 with the reaction times in
minutes as labelled. (c) The percentage cleavage of the C3
α-chain by factor I and the FH Tyr402 and His402
allotypes is shown as a function of reaction time. The
[Zn] values are labelled as shown. The Tyr402 allotypes
are in blue (013HH, ●; 022LM, ▲), and the His402
allotypes are in red (015LT, ○; 032KO, Δ).in vivo. Our assays with the FH allotypes were
performed at 0.3 mg/ml (1.9 μM), which is
comparable with both its physiological range and
the heterozygous FH concentrations used
previously.21 Thus, the α-chain of C3u was cleaved
by factor I in the presence of the FH Tyr402 allotype
without zinc to produce two major degradation
fragments at apparent sizes of 45 kDa and 75 kDa
(Fig. 9a), and the cleavage rate was significantly
reduced in the presence of 200 μM zinc (Fig. 9b).
The influence of zinc on this reaction for both FH
allotypes was investigated at concentrations of
0 μM, 120 μM, and 200 μM (Fig. 9b). This revealed
that the C3u cleavage rate was decreased by zinc, in
good agreement with the decrease seen previously
725Zinc Binding to Homozygous CFHfor heterozygous FH.21 No difference between the
Tyr402 and the His402 allotypes was seen (Fig. 9c).
If similar levels of FH oligomerisation with both
allotypes accounted for the decrease in FH activity
by blocking FH access to C3u and/or factor I,21 this
would account for the observed reduced rate of
C3u cleavage.
Bioinformatics prediction of zinc binding sites
on full-length FH
In order to validate the experimental data analyses
above, we applied two independent bioinformatics
strategies in order to predict potential tetrahedral
zinc binding sites in FH. The first strategy utilised a
distance-dependent, knowledge-based method that
was based on known zinc binding sites. A total of
3705 proteins with Zn binding sites was identified in
the Protein Data Bank (PDB), and these were
screened to identify the residues that were within
0.3 nm of the metal site. Zinc binding sites at the
interface between two protein surfaces generally
contain Asp, His, and Glu side chains as zinc
coordination sites.46 Cys residues were not included
in this survey because there are no exposed Cys
residues in full-length FH. Accordingly, a total of
830 zinc binding sites composed of His, Glu, and/or
Asp residues only was identified and classified into
33 subgroups based on their compositions. A
contact matrix (CM) was defined for each subgroup
that is based on the mean separation±1 SD between
the α-carbon atoms and that between the β-carbon
atoms (Materials and Methods). This matrix was
used to screen the FH domains in order to predict
potential interface zinc binding sites. For this, crystal
and NMR structures for 11 SCR domains and 9
homology-modelled structures that were available
at the time of this work were used (Table 1a).28,55–58
A total of 202 possible partial zinc binding sites was
identified as residue pairs or triplets that could act as
one-half of a tetrahedral zinc interface binding site.
In some cases, a pair or triplet of residues could form
a partial zinc binding site with more than one
coordination geometry (Table 1b). In order of
probability, 31% of these sites were identified in
SCR-6, which had 62.5 sites, followed by 12% in
SCR-3, 10% in SCR-16, 7% sites in SCR-2, and 7%
sites in SCR-14. Two or fewer predicted zinc binding
sites were found in five SCR domains (Table 1a). All
the triplets were located in SCR-6 or between SCR-6
and SCR-7 (Table 1b). The predicted highest number
of zinc binding sites in SCR-6 agrees with the similar
experimentally observed effect of zinc on the
aggregation of both full-length FH and SCR-6/8.
The predicted involvement of SCR-2, SCR-3, and
SCR-16 would explain the ultracentrifugation
experiments with SCR-1/5 and SCR-16/20 that
suggest that other weak zinc binding sites may be
present, assuming that these additional sites sup-plement the zinc-binding role of the His-tag. Even
though the disease-related His402 residue may be a
potential zinc-binding residue, His402 occurred in
only 2 out of the 202 zinc binding sites predicted in
FH. The Tyr402His polymorphism thus has a low
probability of altering the interaction with zinc, and
this agrees with the experimentally observed lack of
difference between the Tyr402 and the His402
allotypes of FH and SCR-6/8 after zinc addition by
ultracentrifugation and scattering.
The second bioinformatics strategy was based on
submitting the 20 crystal, NMR, and homology SCR
structures to web servers that predict metal binding
sites in proteins (Materials and Methods). METSITE
was developed using relative residue positions and
does not require side-chain atoms to be present;
therefore, this is applicable to low-resolution
structures.59 It has a high sensitivity of 94.6% and
a medium specificity of 47.8% for zinc. This method
is based on recognizing residue environments in
which ametal ion is likely to be foundwithin 0.7 nm.
These environments are represented by structural
features such as residue β-carbon distances and
solvent accessibility. When a 0.4-nm threshold was
applied to the METSITE results, METSITE predicted
that 26 out of 175 His, Asp, and Glu residues in FH
were candidates for 13 predicted interaction sites
with zinc. SCR-6 with five residues gave the highest
total among the 20 SCR domains, followed by SCR-
15 and SCR-20 with three each. A ranking based on
the number of residues per zinc binding site
(between 1.3 and 1.4) showed that SCR-6, SCR-7,
SCR-8, SCR-15, and SCR-20 were the most likely
domains to contain zinc binding sites.
Given this outcome from both bioinformatics
strategies, the crystal structure of SCR-6/8 (PDB
code 2UWN) was examined to see whether
tetrahedral zinc binding sites were possible in
SCR-6/8 dimers. A total of 195 homodimeric
structures for SCR-6/8 was created using four
different protein docking servers (Materials and
Methods). All 195 dimeric structures were subjected
to zinc binding site prediction using the web servers
METSITE and CHED (Materials and Methods).
METSITE identified possible tetrahedral zinc bind-
ing sites in 193 out of 195 structures, while CHED
with no activated filters identified possible zinc
binding sites in 91 out of 195 structures. The
difference is attributed to the higher sensitivity but
lower selectivity of METSITE compared to
CHED.59,60 The 10 most frequent possible zinc
binding site residues in the 195 dimeric structures
were Glu359, His360, His371, Asp370, Asp485,
His332, His417, Glu462, Glu487, and Asp497 in
order of frequency (Table 2). Interestingly, His402
was not included in those 10 residues. This provides
an explanation with the experimental observations
of the lack of difference in oligomerisation between
the two SCR-6/8 allotypes in the presence of zinc. In
Table 1. Prediction of partial zinc binding sites in FH
a. Distribution of predicted zinc coordination sites in 20 SCR domains
Domain Structure Sitesa
SCR-1 2RLP 6
SCR-2 2RLP, 2RLQ , 2RLQ 14.5
SCR-3 2RLQ 23.5
SCR-4 Homology 2
SCR-5 NMR structure 0
SCR-6 2UWN 62.5
SCR-7 2UWN 8.5
SCR-8 2UWN 1
SCR-9 Homology 5
SCR-10 Homology 4
SCR-11 Homology 14
SCR-12 Homology 9
SCR-13 Homology 8
SCR-14 Homology 4
SCR-15 1HFH 7.5
SCR-16 1HFH 19.5
SCR-17 Homology 0
SCR-18 Homology 1
SCR-19 2G7I 7.5
SCR-20 2G7I 4.5
b. Possible predicted zinc binding sites in the FH fragment SCR-6/8b
Residues Location Possible zinc coordination
D326–D329 SCR-6 DDH, DDHH
D329–H332 SCR-6 DDHH, DHHH
H332–D358 SCR-6 DDDH, DDHH, DEHH, DH, DHH, DHHH
H332–D358–E359 SCR-6 DEHH
H332–D358–H360 SCR-6 DDHH, DEHH, DHH, DHHH
H332–D358–E362 SCR-6 DDHH, DEHH
H332–E359 SCR-6 EH, EHH, EHHH
H332–H360 SCR-6 DDHH, DEHH, DHH, DHHH, EHH, HH, HHH
H332–H360–E362 SCR-6 DEHH
H332–H360–E433 SCR-6/7 DEHH
H332–E362 SCR-6 DEHH, EHH, EHHH
H332–E433 SCR-6/7 EHHH, DEH, DEHH
H337–E338 SCR-6 EH, EHHH
D358–E359 SCR-6 DE
D358–H360 SCR-6 DDHH, DH, DHH, DHHH
D358–H360–E362 SCR-6 DEHH
H360–E362 SCR-6 DEHH, EEEH, EEHH, EH, EHHH
H360–E433 SCR-6/7 EHH, DEHH, EHHH
D370–H371 SCR-6 DDHH, DEHH, DHH
D370–H371–H373 SCR-6 DDHH, DHH, DHHH
D370–H373 SCR-6 DDHH, DHH, DHHH
H371–H373 SCR-6 DHHH, EEHH, EHH, HHH, HHHH
H373–D377 SCR-6 DHHH, DDHH
E395–H402 SCR-7 EHH, EHHH
E395–H417 SCR-7 DEHH, EHH, EHHH
D454–E456 SCR-8 DDH, DDE
a Zinc coordination sites that are shared between two adjacent SCR domains are counted as 0.5 per domain.
b His402 occurred in 2 of the 76 possible zinc coordinations in SCR-6/8. Zinc coordinations that contain two or three residues also
contain two or one H2O molecules, respectively, to form the required tetrahedral geometry with zinc.
726 Zinc Binding to Homozygous CFHorder to rationalise the outcome of these searches, we
analysed the 195 putative dimeric structures with
RMSDCLUST (Materials andMethods), which super-
poses every pair of structures and identifies clusters
of similar structures. Nine different zinc binding sites
were found in seven clusters that each contained 18,
15, 4, 2, 3, 4, and 5 SCR-6/8 dimer structures, together
with a single outlier that did not belong to any cluster.Only two out of the nine possible zinc binding sites
possessed all the residues identified as the 10 most
frequent possible zinc-binding residues. One of these
binding sites involved Glu359 and His360 on each of
two SCR-6/8 monomers (Fig. 10a), and the other
involved His371 on one SCR-6/8 monomer and
Asp485 and Glu487 on the other monomer (Fig. 10b).
If zinc cross-links pairs of SCR domains in tetrahedral
Table 2. The most likely zinc interaction ligands in FH SCR-6/8 and three protein benchmarks
FH SCR-6/8
(PDB code 2UWN)
Human interferon β
(PDB code 1AU1)
Complex of human growth hormone
and prolactin (PDB code 1BP3)
Archaeal cytochrome P450
(PDB code 1F4T)
Top 3 Glu359 Glu42 His18a Asp52
His360 His93a Glu174a His340
His371 His121a Asp387a Glu342
Top 5 Asp370 Glu85 His21 Asp42
Asp485 His131 His388a His178a
Top 10 His332 Glu81 Glu56 Glu48
His417 His97a Asp171 Asp52
Glu462 Glu103 Glu245 Glu139a
Glu487 Glu292 Glu274
Asp497 Glu345 Asp294
a The original ligands in the three benchmarked structures 1AU1, 1BP3, and 1F4T.
727Zinc Binding to Homozygous CFHcoordinations, the predictions in Fig. 10a and b lead
to a schematic cross-linking cartoon in which
adjacent pairs of two SCR-6 domains or SCR-6 and
SCR-8 domains form contacts with each other. The
indefinite self-association suggested in Fig. 10c
shows how zinc may cross-link SCR-6/8 molecules
to form large aggregates. As a control of this
predictive approach, the same procedure was
performed with three protein structures with
known zinc binding sites (Table 2). These were
human interferon-β, the complex of human growth
hormone and prolactin, and an archaeal cytochrome
P450. All the known zinc-binding residues in the
three known protein structures were correctly
included in the top 10 most frequently occurring
residues, and this outcome supports the credibility
of this predictive method for FH SCR-6/8.Conclusions
This investigation of FH–zinc interactions fol-
lowed the observation that sRPEds and the Bruch's
membrane in postmortem human tissues contain
unexpectedly high concentrations of zinc, including
abundant bioavailable ions (ionic and/or loosely
protein bound).42 Zinc accumulation was especially
high in the maculae of eyes with AMD.42 There, the
total extracellular zinc was measured to be
hundreds of parts per million, which is equivalent
to zinc concentrations of several millimolar. Most of
the zinc will be inaccessible for reason of its tight
binding to components within drusen. The evidence
for bioavailability arises from the use of fluorescent
probes because these only bind to bioavailable
zinc.42 The bioavailability of only 1% of this
millimolar zinc in the extracellular space is sufficient
to cause our FH–zinc complexes to aggregate.21
While further experimental evidence for this level of
zinc bioavailability in vivo in relation to AMDwill be
required, metal-induced protein aggregation has
been shown to be significant in other degenerative
diseases such as in amyloid and prion diseases.61Under pathophysiological conditions, normal phys-
iological/chemical buffering mechanisms will be
compromised, and the basal level of nanomolar or
picomolar free zinc ion concentrations can increase
substantially.62 Our zinc concentrations from 10 μM
upwards, at which we observed the effects with FH,
therefore have biomedical significance.
Such interactions of extracellular proteins with
micromolar concentrations of zinc ions (as illustrated
here for FH–zinc) are deemed physiologically
relevant based on total zinc concentrations. During
neuronal activity, Zn is released into the synaptic
cleft and can reach concentrations of 300 μM.63 Zinc
inhibition constants in micromolar ranges for kallik-
reins and carboxypeptidase A are also likely to be
physiologically relevant because these enzymes are
secreted from tissues that also secrete zinc ions. It is
however stressed that this is not the case for
intracellular proteins. The total cellular zinc concen-
tration can be as high as several hundred micro-
molars, especially in the nervous system (which
includes the eye).64 In these cells, the cytosolic
bioavailable free zinc ion concentration is in pico-
molar ranges, and zinc-binding proteins have very
low Kd values to match these.
65,66
Overall, this study has located a major FH zinc
binding site to lie within the functionally important
SCR-6/8 domains, and this accounts for the inhibi-
tion of FH activity by zinc. Our two earlier studies
showed that heterozygous FH aggregated in the
presence of five transition metals at physiological
FH concentrations, particularly at zinc and copper
concentrations of ≥10 μM.20,21 Zinc has the stron-
gest effect on FH and inhibits its function. In this
study, using ultracentrifugation and X-ray scatter-
ing, we have shown that similar zinc-induced
aggregation occurs for both the homozygous forms
of FH with either the Tyr402 or the disease-related
His402 allotype. The FH Val62 or Ile62 polymor-
phism (which is also disease related) also has no
influence on zinc binding effects. Therefore, zinc-
induced aggregation is independent of FH genetic
heterogeneity. Based on ultracentrifugation and
Fig. 10. Predicted structural models for zinc binding to SCR-6/8. The twomost likely predicted SCR-6/8 zinc sites from
docking simulations are shown in (a) and (b), and a cartoon of the resulting putative zinc-induced SCR-6/8 aggregation is
shown in (c). (a) A predicted zinc binding site is composed of two Glu359 and His360 side chains (Table 2) at the surface
interface between two SCR-6 domains in the docked dimer. The left panel shows a close-up view of the zinc-binding
residues, while the right panel shows the overall structure of the putative dimer. The distances between each zinc ligand
atom (nitrogen or oxygen) are displayed in nanometers. (b) A second predicted zinc binding site is composed of a His371
side chain in SCR-6 of the first SCR-6/8 monomer and the Asp485 and Glu487 side chains in SCR-8 of the second SCR-6/
8 monomer (Table 2). Other details follow (a). (c) A mechanistic model for the zinc-induced aggregation of SCR-6/8 based
on the two possible zinc binding sites shown in (a) and (b) shows how the two zinc sites may form a daisy chain of SCR-6/
8 that leads to aggregation and precipitation.
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729Zinc Binding to Homozygous CFHscattering data, which were validated by bioinfor-
matics predictions, we showed that SCR-6/8 is a
major locus for zinc-induced aggregation through
the presence of partial zinc binding sites at the FH
surface. These sites can be cross-linked in the
presence of zinc to form large oligomers. This
daisy-chained cross-linking scheme is explained in
terms of putative SCR-6/SCR-6 interactions that
alternate with putative SCR-6/SCR-8 interactions
(Fig. 10c). Control experiments with the other two
functionally active regions of FH at SCR-1/5 and
SCR-16/20 showed that both regions may also
aggregate in the presence of zinc. However, further
controls with added nickel indicated that this is less
significant than that at SCR-6/8. This study now
explains the zinc-induced formation of FH oligo-
mers for the first time in terms of multiple weak
surface zinc binding sites that are located primarily
within the SCR-6/8 region. The compact nature of
these FH oligomers (Fig. 8) is explained by zinc
binding at a central location in FH within SCR-6/8.
The proximity of SCR-6/8 to the C3b-binding region
of FH at SCR-1/5 explains why zinc binding inhibits
FH; in addition, the SCR-6/8 domains bind to
heparin and C-reactive protein. It was interesting
that the Tyr402 or His402 allotype has no significant
influence on zinc-induced aggregation, given that
His402 might have been a potential surface zinc-
binding residue.
FH is a major complement regulator in blood and
is expressed and secreted by many different cell
types including the RPE.67 The major physiological
ligands of FH include C3b and its C3d fragment,
heparin and other glycosaminoglycans, and C-
reactive protein and FH self-association, in addition
to zinc binding.30,31 All these ligands bind weakly to
FH with micromolar affinities, and this is consistent
with the relative micromolar abundance of FH in
serum. The FH–zinc interaction has already been
discussed previously.21 Since that 2008 study, more
recent studies show that C3b and C3d bind with Kd
values of 3.5–14 μM and 2.6 μM, respectively,12,68 C-
reactive protein binds with a Kd value of 4–15 μM,
13
and FH dimerises with a Kd value of 28 μM.
19 If FH
is found at 0.6 mg/ml in serum, this means that 11%
of FH exists as dimers. If C3b occurs at 1 mg/ml,
29% of FH will be bound to C3b if the Kd value is
3.5 μM. If C-reactive protein occurs at the acute-
phase level of 0.4 mg/ml, 32% of FH will be bound
to C-reactive protein if the Kd value is 4.2 μM. These
calculations assume that no other factors in serum
influence these equilibria, which have been consid-
ered separately from each other for the purpose of
illustration here. In comparison to these physiolog-
ical interactions, the pathophysiological interaction
between FH and zinc is characterised by comparable
Kd values at approximately 10 μM, implying that FH
will be 50% bound to zinc if bioavailable zinc is
present at 10 μM. However, most of the zinc inplasma is bound to proteins such as human serum
albumin (HSA),69 and only a small proportion of
this zinc is bioavailable in plasma.65 Potentially
higher bioavailable zinc levels may exist in Bruch's
membrane (see below). Because two of the most
frequently predicted zinc-binding residues, His360
and His371 (Table 2), have been implicated in
glycosaminoglycan binding to FH,57 it is possible
that zinc binding to FH can perturb the binding of
glycosaminoglycans to FH.
The comparison of zinc binding to FH and HSA is
of interest. HSA is a three-domain protein that
circulates in serum at reference levels between 30
and 50 mg/ml (450–750 μM).69 HSA binds 84% of
plasma zinc, and α2-macroglobulin binds 15%.66 In
HSA, a zinc binding site was identified at the protein
surface interface between domain I at His67 and
Asn99 and domain II at His247 and Asp249 (PDB
code 1AO6) that is conserved in almost all mamma-
lian species.69,70 Here, asparagine is a rare zinc-
binding ligand. Being stereochemicallywell-defined,
the Kd for zinc binding to HSA is lower at 1 μM
compared to that of approximately 10 μM for zinc
binding to FH. The larger Kd value for the FH–zinc
interaction is explained by the lack of proximity in
monomeric FH of appropriate pairs of the SCR
domains that possess potential zinc-binding resi-
dues. Given the HSA concentration of 450–750 μM
and the serum zinc concentration of 12.5 μM, where
HSA binds 84% of plasma zinc, the presence of HSA
will reduce the level of bioavailable zinc, and
accordingly, there is little risk of FH aggregation
with zinc in plasma. The total zinc level in plasma
remains steady at 14.7 μM even after a daily diet
supplement with 80 mg zinc in the AREDS
trials.43,71 Therefore, since bioavailable zinc in
plasma occurs in a 20- to 210-pM range,65 normal
zinc levels in plasma are too low to induce FH
oligomerisation.
Human ocular tissues contain unusually high
concentrations of zinc.40 Zinc appears to be essential
for the normal function of the retina, but its exact
role is not clear.41 In the RPE–choroidal complex,
zinc is expected to be mostly bound to melanin,
metallothionein, and other zinc-binding proteins,
and it has been proposed that less than 10% of zinc
in the retina is free or chelatable.40,41,72 RPE cells can
accumulate zinc following oral supplementation
and retain it longer than any other tissues in the
body, but zinc might be released from the RPE
through cellular damage.72 The released zinc could
then be available in the Bruch's membrane or be
entrapped in sRPEds and contribute to the several
hundred parts per million of zinc (mM) observed in
sub-RPE deposits.41,42 This RPE-released zinc might
be sufficient to induce a localised aggregation of FH
that has been recruited to the location because of
inflammation associated with RPE damage. The
comparison above with the Kd values for FH
730 Zinc Binding to Homozygous CFHinteractions with its other ligands shows that the
regulatory balance of FH activity in terms of
interactions with C3b, heparin, and C-reactive
protein can be disturbed by zinc binding. The
main interaction of zinc with the SCR-6/8 regions,
which is a locus for interactions with heparin and C-
reactive protein, indicates that FH function with
these two ligands will be perturbed if sufficient
excess zinc is available. In addition, the indefinite
self-association of FH at SCR-6/8 is expected to
block the binding of the neighbouring FH SCR-1/4
domains to C3b. Such a mechanism can contribute
to both the formation of sRPEds and the inhibition of
the regulatory function of FH to cause inflammation
and host cell damage.
Daily supplements with 80 mg zinc, 2 mg copper,
vitamins C and E, and β carotene are recommended
by AREDS as a means of reducing the risk for
progression to advanced AMD.43,44 Interestingly, the
AREDS-recommended zinc supplements with anti-
oxidants were recently correlated with a greater
reduction in progression to advanced AMD in
patients who are homozygous for the FH Tyr402
allotype (wild type; 34% of cases) compared to
patients who are homozygous for the FH His402
allotype (AMD risk; 11% of cases).45 Our current
study offers no direct explanation for this observation
because no significant difference in zinc-induced FH
aggregation was seen between the Tyr402 and the
His402 allotypes of FH and SCR-6/8 (Figs. 2 and 7).
The most common coordination geometry of zinc
binding sites is tetrahedral.46 Here, our bioinfor-
matics analyses showed that 3705 zinc binding
coordinations were available for analysis from the
PDB. Protein interface zinc binding sites are primar-
ily supplied by His, Glu, and Asp residues, but sites
containing Cys are also found (not relevant to FH
because it contains no free Cys residues), and β-sheet
secondary structures predominately contribute to
zinc binding sites. Zinc binding is able to induce
protein self-association or link two different
proteins.46 Our previous discussion of potential FH
zinc binding sites21 is now clarified by the abun-
dance of partial zinc sites that were predicted using a
distance-based algorithm, suggesting that multiple
weak zinc binding sites exist in FH if zinc cross-
linked FH. This outcome predicts that a range of
different zinc-induced oligomers will form at several
sites. This multiplicity of oligomers is in good
agreement with the observation of many overlap-
ping peaks in the ultracentrifugation c(s) size
distribution analyses (i.e., the opposite of the
formation of fewer well-resolved signals such as
the nine peaks observed for FH alone8,19) and also
with the formation of indefinite oligomers at high
zinc concentrations. The prediction of multiple sites
also explains better why different types of FH
oligomers were observed with different metals
such as copper.21 Finally, the predictions were alsoinformative in that they explained the lack of
difference seen between the SCR-6/8 Tyr402 and
the His402 allotypes because His402 was not
predicted to be a significant zinc-binding ligand.
These analyses provide insight into the weak
binding of zinc to other plasma proteins. It is possible
that the outcome of this FH–zinc study will be
applicable to other plasma proteins. For example, we
have observed that zinc will induce oligomer
formation in C3 (K. Li and S.J.P., unpublished data).
In summary, our results contribute to a better
understanding of how zincmight be involved in two
distinct and different ways that contribute to
AMD.73 In early AMD, zinc release may trigger
sRPEd formation and contribute to the growth of
these deposits through oligomerisation of proteins
including FH. This will lead not only to deposit
formation but also to uncontrolled inflammation,
the two hallmarks for the development of this
blindness condition. In late AMD, however, zinc
supplementation could slow disease progression
through a currently unidentified mechanism. This,
however, is unlikely to involve FH oligomerisation.Materials and Methods
Protein purification of FH and FH SCR-6/8
Human blood was obtained from 48 anonymous,
genotyped, healthy volunteers following ethical approval.
Direct DNA sequencing of the PCR product of the FH gene
was used to identify the Tyr402His and Val62Ile FH
polymorphisms in each volunteer. Four homozygous FH
Tyr402 allotypes (coded 026II, 022LM, 018DK, and 016CC)
and four FHHis402 allotypes (coded 027BA, 032KO, 030TJ,
and 033NV) were purified using monoclonal affinity
chromatography with an MRC-OX23 Sepharose
column.19,74 The four Tyr402 allotypes were homozygous
for Ile62, homozygous for Val62, heterozygous for Val62/
Ile62, andhomozygous forVal62 in that order,while all four
His402 allotypes were homozygous for Val62. Native factor
I was purified from a pool of just-outdated anonymised
human plasma using another monoclonal affinity MRC-
OX21 Sepharose column for factor I.19,74 Bound homozy-
gous FH and native factor I were each eluted from the
columns using 3 M MgCl2, pH 6.9, and then each was
dialysed in Hepes buffer (10 mMHepes and 137 mMNaCl,
pH 7.4) in the presence of 0.5 mM EDTA to remove Mg2+.
TheMRC-OX23 columnwaswashedwith guanidine (0.2M
Tris and 4 M guanidine–HCl, pH 8.0) after each FH
preparation to avoid allotype cross-contamination. IgG
contaminants were removed by passing the FH and factor I
purifications through a Hitrap™ Protein GHP. Nonspecific
aggregates and HSA were removed by gel filtration on a
Superose™ 6 prep grade XK 16/60 size-exclusive column.
Native C3 was purified from fresh plasma by ion-exchange
chromatography, and haemolytically inactive C3 in which
the reactive thioester is hydrolysed (C3u) was prepared by
incubating native C3 in 200mMhydrazine at 37 °C for 1 h.75
The recombinant FH fragment SCR-6/8 Tyr402 was
731Zinc Binding to Homozygous CFHexpressed in BL21 (DE3) Escherichia coli cells using a
pET21ab vector system, while SCR-6/8 His402 was
expressed in BL21 (DE3)pLysS E. coli cells using a pET14b
vector system. SCR-6/8 was extracted from inclusion
bodies, solubilised, and refolded. The refolded SCR-6/
8was purified byusing ion-exchange chromatography with
a Hitrap™ 5-ml Heparin HP column (A.M. and S.J.P.,
unpublished data).17 The purifications of SCR-1/5 and
SCR-16/20 are described elsewhere.18 Proteins were
dialysed in Hepes buffer for zinc experiments because
Hepes does not interact with zinc. Protein concentrations
were determined from absorption coefficients of 16.2 for
full-length FH Tyr402 and 16.1 for full-length FH His402,
12 for factor I, 9.4 for C3u, 17.2 for SCR-1/5, 22.7 for SCR-
6/8 Tyr402, 22.1 for SCR-6/8 His402, and 15.7 for SCR-
16/20 (1%, 280 nm, 1-cmpath length).6,7,18,76,77 The integrity
of protein samples was routinely checked by SDS-PAGE
before and after scattering and ultracentrifugation experi-
ments.Sedimentation velocity data collection and analyses
AUC data were obtained on two Beckman XL-I
instruments equipped with AnTi50 or AnTi60 rotor using
two-sector cells with column heights of 12 mm at rotor
speeds of 50,000 rpm and 60,000 rpm. Sedimentation
velocity experiments at 20 °C were performed for the two
FHTyr402 allotypes (026II and 022LM) and the twoHis402
allotypes (027BA and 032KO) at 0.7–0.8 mg/ml, which
were titrated with ZnSO4 at concentrations of 0.2 μM,
2μM, 6μM, 20μM, 60μM, 120 μM, and 200 μM. SCR-1/5 at
0.3 mg/ml was titrated with ZnSO4 at concentrations of
0 μM, 2 μM, 6 μM, 20 μM, 60 μM, 200 μM, and 600 μM. The
Tyr402 and His402 allotypes of SCR-6/8 at 0.3 mg/ml
were titrated with ZnSO4 at concentrations of 0.2 μM,
2 μM, 6 μM, 20 μM, 60 μM, 200 μM, 300 μM, and 600 μM.
SCR-16/20 at 0.1 mg/ml was titrated with ZnSO4 at
concentrations of 0 μM, 2 μM, 20 μM, 200 μM, and 600 μM.
Data analyses were performed using the SEDFIT software
(version 11.71).78,79 The distribution analyses c(s) provided
size and shape data by directly fitting the boundary
Lamm equation to 350 scans for FH, 480 scans for SCR-
1/5, 640 scans for SCR-6/8, and 440 scans for SCR-16/20.
The c(s) analyses were based on a fixed resolution of 200
and floated the meniscus, the bottom of the cell, the
baseline, and the average frictional ratio f/fo starting
from 1.781 for FH and from 1.200 for SCR-6/8 until the
overall root-mean-square deviation (RMSD) and fits
between the observed and the calculated sedimentation
boundaries were satisfactory. The f/fo values were fixed
at 1.45 for SCR-1/5, 1.35 for the SCR-16/20 monomer,
and 1.58 for the SCR-16/20 dimer.18 Monomer and
oligomers were quantitated using the integration func-
tion in the c(s) analyses. The percentage fraction of
monomer and oligomers of full-length FH was derived
by assuming that the sum of the signal intensities of
monomer and oligomer was 100%. Other details are
described elsewhere.18,19X-ray scattering data collection and analysis
X-ray scattering data were acquired for the FH allotypes
in one beam session and for the SCR-6/8 allotypes in asecond beam session on Beamline ID02 at the European
Synchrotron Radiation Facility (Grenoble, France) operat-
ing with a ring energy of 6.0 GeV in 4-bunch mode and 16-
bunch mode in the two beam sessions, respectively, to
reduce the incident flux.80 Storage ring currents were 29–
43 mA in the first beam session and 56–91 mA in the
second beam session. The sample–detector distances were
3 m for the first beam session and 1.5 m for the second
beam session. Potential radiation damage was eliminated
by the continuous movement of the sample in a flow cell
during beam exposure, the use of 10 time frames of
duration between 0.1 s and 0.25 s each during each
acquisition, and on-line checks for the absence of radiation
damage at low Q. In the first beam session, the FH Tyr402
allotypes 018DK and 016CC and the His402 allotypes
030TJ and 033NVwere studied at 0.9 mg/ml (5.8 μM)with
ZnSO4 at concentrations of 0.2 μM, 2 μM, 6 μM, 20 μM,
60 μM, 120 μM, 200 μM, and 600 μM. In the second beam
session, the Tyr402 and His402 allotypes of SCR-6/8 were
studied at 0.2 mg/ml (9.7 μM) with ZnSO4 at concentra-
tions of 0.2 μM, 2 μM, 6 μM, 20 μM, 60 μM, 120 μM,
200 μM, 300 μM, and 600 μM. All the measurements were
performed in Hepes buffer (10 mM Hepes and 137 mM
NaCl, pH 7.4). Other details including data reduction are
described elsewhere.17,18
In a given solute–solvent contrast, the radius of gyration
RG corresponds to the mean square distance of scattering
elements from their centre of gravity and is a measure of
structural elongation. Guinier analyses at low Q give the
RG value and the forward scattering at zero angle I(0) from
the expression:50
ln I Qð Þ¼ ln I 0ð Þ − R 2G Q2=3
This expression is valid in a QRG range of up to 1.5. The
I(0)/c value (c is the protein concentration in milligrams
per milliliter) is proportional to the relative molecular
mass Mr. If the structure is elongated, the mean cross-
sectional radius of gyration RXS and the cross-sectional
intensity at zero angle [I(Q)Q]Q→ 0 are determined from
Guinier analyses in a Q range larger than that used for the
RG determination:
50
ln I Qð ÞQ½ ¼ ln I Qð ÞQ½ QY0 − R 2XS Q2=2
The Guinier analyses were performed using the interac-
tive PERL script program SCTPL7 (J. T. Eaton and S.J.P.,
unpublished software) on Silicon Graphics OCTANE
Workstations.
Indirect transformation of the I(Q) curve measured in
reciprocal space into real space gives the distance
distribution function P(r) and was carried out using the
program GNOM:81
P rð Þ = 1
2k2
Zl
o
I Qð ÞQr sin Qrð ÞdQ
P(r) corresponds to the distribution of distances r between
volume elements. This offers an alternative calculation of
the RG and I(0) values that is based on the full scattering
curve I(Q), and not that at low Q. It also gives the most
frequently occurring distance M and the maximum
dimension of the macromolecule L. For FH at 0.9 mg/ml
titrated with zinc, the X-ray curves utilised up to 344 data
732 Zinc Binding to Homozygous CFHpoints for Q between 0.08 nm−1 and 1.60 nm−1. Other
details are described elsewhere.6,17–19Fluid-phase activity assays
To determine activities, we incubated the reaction
mixtures containing 0.3 mg/ml FH, 0.3 mg/ml C3u, and
0.003 mg/ml factor I in a water bath at 37 °C in three
concentrations of ZnSO4 (0 μM, 120 μM, and 200 μM).
The functions of two pairs of the two allotypes of FH
were tested. The FH Tyr402 allotype 013HH and the FH
His402 allotype 015LT were tested with 0 μM and
200 μM zinc, and the FH Tyr402 allotype 022LM and
the His402 allotype 032KO were tested with 120 μM zinc.
At timed intervals, 5-μl aliquots were removed for
reducing SDS-PAGE analyses. Three blank controls were
used, namely, 0.3 mg/ml C3u; 0.3 mg/ml C3u, and
0.3 mg/ml FH and 0.3 mg/ml C3u, 0.3 mg/ml FH, and
zinc. The C3 α-chain band densities from SDS-PAGE
were measured using the gel analysis system SYNGENE
(Synoptics Ltd., Cambridge, UK). The C3 α-chain
cleavage was referenced to the averaged density of the
uncleaved bands in the controls.†http://bioinf.cs.ucl.ac.uk/metsite
‡http://cluspro.bu.edu/login.php
§http://www.csd.abdn.ac.uk/hex_server/
||http://bioinfo3d.cs.tau.ac.il/PatchDock/
¶http://rosettadock.graylab.jhu.edu/
a http://ligin.weizmann.ac.il/~lpgerzon/mbs4/mbs.
cgiMolecular prediction of surface zinc binding sites
Two independent database analyses were used to
predict partial protein-interface-type zinc binding sites
on protein surfaces. In the first one, a data set of 3705 Zn-
binding protein crystal structures with resolutions better
than 0.3 nm was identified from the PDB. Residues that
were located within 0.3-nm distance of the zinc atom
were assigned as putative zinc-coordinating residues
using a PERL script to scan the PDB. Of the 4883
putative zinc binding sites that were identified, a total of
830 zinc binding sites composed of His, Glu, and/or Asp
as zinc coordination residues was analysed and classified
into 33 subgroups based on the amino acid composition
of each site. In each subgroup, the distance x between the
Cα atoms i and that between the Cβ atoms j of each zinc-
coordinating residue were calculated as a residue pair
type x(i,j) and stored in a CM (contact matrix). For each
residue pair in CM, the average distance x ̄ and its
standard deviation σ were calculated. An algorithm was
implemented to screen each protein structure of interest
for residues that form putative partial Zn binding sites.
For a given protein structure, solvent-exposed Asp, His,
and Glu side chains were identified. A residue is
considered exposed if its side chain has a relative surface
accessibility greater than 20%. The geometric distances
between pairs and triplets of Cα atoms and Cβ atoms of
the putative zinc-coordinating residues were calculated.
If these distances fall within the distance cutoff x̄±σ,
then the pair or triplet of residues become considered as
possible zinc-coordinating residues. Using this algorithm,
we screened 11 experimental SCR crystal or NMR
structures for SCR-1/2, SCR-2/3, SCR-5, SCR-6/8, SCR-
15/16, and SCR-19/2028,55–57 and 9 homology-modelled
SCR structures for SCR-4, SCR-9, SCR-10, SCR-11, SCR-
12, SCR-13, SCR-14, SCR-17, and SCR-18.28
The second prediction of partial metal binding sites in
FH was carried out using web servers. In this, the 20
experimental and homology SCR structures in FH wereevaluated using METSITE†,59 which uses a set of neural
network classifiers trained to identify potential cation
sites. Following this analysis, potential zinc sites at
dimer interfaces were studied. To form FH dimer
structures, we docked the SCR-6/8 His402 crystal
structure (PDB code 2UWN) using four different dock-
ing approaches available as web servers including
ClusPro‡, HEX§, PatchDock||, and RosettaDock¶.82–87
These four docking programs were selected according to
their performance in the Critical Assessment of Predicted
Interactions surveys.88 These possible dimeric structures
were tested again by METSITE and another web server,
CHED,60 to detect possible tetrahedral zinc binding sites
at the protein interface in the dimeric structures. The
CHED web servera searches for Cys, His, Glu, and Asp
residues with atoms within several specified distances to
each other and a 0.27-nm distance to the putative zinc
atom position. If the distances do not match, an
independent rotamer library is used to find an appro-
priate fit configuration. The sites found in CHED are
filtered by a decision tree and a support vector machine
to verify their suitability. The dimeric structures that
possess zinc binding sites predicted by METSITE and
CHED were clustered using the program RMSDCLUST
(D.T.J., unpublished software) to group similar struc-
tures. RMSDCLUST carries out rigid-body superposition
between each pair of dimeric structures, computes the α-
carbon RMSD, and then clusters all pairs of structures
within an adjustable RMSD threshold (0.6 nm in this
case). To validate the methods, we performed the same
predictions with three zinc binding structures as bench-
marks, namely, human interferon-β (PDB code 1AU1),
the complex of human growth hormone and prolactin
(PDB code 1BP3), and thermophilic cytochrome P450
from Sulfolobus solfataricus (PDB code 1F4T).89–91
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